



RECEIVED #10/a
NOV 26 2002 Dmt
TECH CENTER 1600/2900 12902

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 016754-0206

Applicant: David M. ANDERSON *et al.*
Title: ENZYME TREATMENT
Appl. No.: 09/731,971
Filing Date: December 08, 2000
Examiner: Manjunath N. Rao
Art Unit: 1652

REPLY AND AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Box NON-FEE AMENDMENT
Washington, D.C. 20231

Sir:

This communication is responsive to the Office Action dated July 24, 2002, concerning the above-referenced patent application.

Please amend the application as follows:

IN THE SPECIFICATION

1. On page 18, lines 2-9, please replace the first full paragraph and replace it with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

a1
The gene coding for phosphatidylinositol specific phospholipase C (PI-PLC) has been sequenced. See Kuppe *et al.*, *J. Bacteriol.* 171:6077-6083, 1989. Using PCR technology, the PI-PLC gene was cloned from *Bacillus cereus* (ATCC 6464) chromosomal DNA. An expression vector, pMEGA (BIO 101, Vista, CA), for *Bacillus megaterium* was used. Two PCR primers, 5'-GACTAGTAATAAGAAGTTAATTTTG-3' (primer 1; SEQ ID NO:1) and 5'-CGGGATCCATATTGTTGGTTATTGG-3' (primer 2; SEQ ID NO:2), were designed with a *SpeI* site in primer-1 (SEQ ID NO:1) and a *BamHI* site in primer-2 (SEQ ID NO:2).

11/25/2002 MBLANCO 00000006 09731971

01 FC:1202
02 FC:1201

594.00 OP
84.00 OP